Nyxoah sees Q4 revenue EUR 1.8M up 40% YoY, sees FY23 revenue EUR 4.3M

Nyxoah announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, Revenue for the fourth quarter of 2023 is anticipated to be approximately EUR 1.8M, a 40% increase over the fourth quarter of 2022 and an 87% increase over the third quarter of 2023. Revenue for the full year 2023 is anticipated to be approximately EUR 4.3 million, a 41% increase over the full year 2022. Ended the year with 48 active German accounts. “We are excited with the strong preliminary fourth quarter sales, which are anticipated to be nearly double from last quarter. This anticipated growth reflects both strong underlying demand for Genio and focus on streamlining the patient referral pathway through initiatives such as our direct-to-consumer online campaigns launched in March,” commented Olivier Taelman, Chief Executive Officer. “This performance throughout 2023 sets the stage for an exciting 2024, as in a few months we expect to report data from our DREAM US pivotal trial, file for FDA approval, begin preparations to enter the US market, and begin to see contribution from the ResMed commercial partnership in Germany.”